Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.65 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.65 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263421 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL17010791 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL15071495 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL309060 | 0.93 | P2RY1 (0.71) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL625113 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL20901220 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14928757 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14948858 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL19442379 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14853693 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4507089-A | Mechanical support module for nucleic acid | TCHUEMPE TCHUENTE GERMAIN (FR) | 1985-03-26 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| CN-114585742-A | Treatment of | 牛津大学创新有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210079440-A1 | HIGH EXPRESSION mRNA SWITCH | KYOTO UNIVERSITY (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3653710-A1 | HIGH EXPRESSION mRNA SWITCH | Kyoto University (JP) | 2020-05-20 | — | — | EP | disclosed |
| EP-3408276-A1 | 5'-PHOSPHOROTHIOLATE MRNA 5'-END (CAP) ANALOGS, MRNA COMPRISING THE SAME, METHOD OF OBTAINING AND USES THEREOF | Uniwersytet Warszawski (PL) | 2018-12-05 | — | — | EP | disclosed |
| CN-108929880-A | Artificial nucleic acid molecules comprising a 5' TOPUTR | 库瑞瓦格股份公司 | 2018-12-04 | — | — | CN | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017130151-A1 | 5'-PHOSPHOROTHIOLATE MRNA 5'-END (CAP) ANALOGS, MRNA COMPRISING THE SAME, METHOD OF OBTAINING AND USES THEREOF | UNIWERSYTET WARSZAWSKI (PL) | 2017-08-03 | — | — | WO | disclosed |
| US-20140141068-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20120156770-A1 | HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-06-21 | — | — | US | disclosed |
| US-8133724-B2 | Human androgen receptor alternative splice variants as biomarkers and therapeutic targets | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100068802-A1 | NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-03-18 | — | — | US | disclosed |
| US-7368551-B2 | Comprises nucleotide sequence coding methyltransferase for use as tool in diagosing tumor disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040234997-A1 | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof | THE GENERAL HOSPITAL CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-4507089-A | Mechanical support module for nucleic acid | TCHUEMPE TCHUENTE GERMAIN (FR) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | CA5A 2713/4885P2RY1 1175/4885TAS1R3 4333/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | CA5A 3654/4885P2RY1 4549/4885TAS1R3 3203/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | CA5A 3735/4885P2RY1 2249/4885TAS1R3 3879/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | CA5A 1929/4885P2RY1 2903/4885TAS1R3 3866/4885 |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MSH2, APAF1, MCL1 | CA5A 1764/4885P2RY1 2770/4885TAS1R3 2745/4885 |
| US-20140141068-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 | MSH2, RNF168, UBE3A | CA5A 2222/4885P2RY1 3953/4885TAS1R3 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.